The9 expects 15%-16% stake in Nanyang Biologics after planned Nasdaq SPAC merger
Reuters2026/08/21 12:32- The9’s investee Nanyang Biologics moved closer to a Nasdaq listing via a planned business combination with RF Acquisition Corp II.
- On Aug. 19, 2026, RFAI shareholders backed the deal, clearing a key step toward trading under ticker “NYB.”
- The9 expects to own about 15% to 16% of the combined Nasdaq-listed company once the transaction closes.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro area: PMIs signal resilient growth – Nomura
After the "bloodbath" in July, faith in AI remains! Goldman Sachs: Hedge funds heavily bet on big tech, Amazon remains the most favored for 11 consecutive quarters
A report from Goldman Sachs shows that turbulence in the US stock market in July triggered the largest deleveraging by hedge funds in nearly a decade, with AI-related positions, which previously led gains, experiencing the deepest corrections. However, capital has not withdrawn from the main sectors, as Amazon has remained the top holding for 11 consecutive quarters, and nine of the ten most popular stocks are related to AI. At the same time, funds have reduced crowding risks by increasing allocations to healthcare, financial, and energy sectors, and have also extended their layouts along industry chains such as data centers and AI infrastructure.
Donegal Mutual Insurance reports $362,931 purchase of Donegal Group Class A shares
SMT Scharf to publish half-year financial report update
